NasoVAX Influenza Vaccine Description
NasoVAX is a recombinant intranasal vaccine that is RD-Ad5-based being developed for both seasonal and pandemic use.
NasoVAX can activate the humoral, mucosal, and cellular immune arms in unison for a more comprehensive immune response.
The data from the Phase 2a trial with a monovalent NasoVAX vaccine indicated that NasoVAX was well-tolerated and achieved 100% seroprotection with serum antibody responses comparable to a licensed injected influenza vaccine.
Statistically significant increases in mucosal antibody were noted as well as a robust T cell response directed against influenza. Approximately half of the subjects from the highest dose were evaluated between 12 and 14 months after initial dosing for additional immunogenicity assessment.
The durability data show that the immune response elicited by NasoVAX was stable with no overall change in the antibody titer or level of seroprotection over an average of 13 months. The combination of serum antibody, mucosal antibody and T-cell response in combination with the durability data provides the potential for improved protection against influenza and suggests that NasoVAX could have a greater impact on flu symptoms and shedding of the influenza virus than currently approved influenza vaccines.
NasoVAX Influenza Vaccine Indication
NasoVAX is indicated to prevent influenza, seasonal as well as pandemic (COVID-19)
NasoVAXInfluenza Vaccine Dosage
NasoVAX is administered by intranasal spray. The dosage is being evaluated in clinical trials.
NasoVAX Influenza Vaccine News
June 1, 2020 - Altimmune Launches Clinical Trial Of T-COVIDTM, An Investigational Intranasal Immune Modulator For The Treatment Of Patients With Early COVID-19. The FDA has agreed that the Company may use its existing lot of RD-Ad5-based NasoVAX influenza vaccine for the planned T-COVID clinical trial allowing the Company to immediately initiate the study.
NasoVAX Influenza Vaccine Clinical Trials
NasoVAX Influenza vaccine continues to be studied in Clinical Trials.